{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:17:43Z","timestamp":1788617863511,"version":"build-2803163510"},"reference-count":32,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Incretin therapies, comprised of the dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have been increasingly utilized for the treatment of type 2 diabetes (T2DM). Previous studies have conflicting results regarding risk of pancreatitis associated with these agents\u2014some suggest an increased risk and others find no correlation. Adverse event reporting systems indicate that incretin therapies are some of the most common drugs associated with reports of pancreatitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study aimed to compare the odds of developing pancreatitis in veterans with T2DM prescribed an incretin therapy versus thiazolidinediones (TZDs: pioglitazone and rosiglitazone) within the Veterans Health Administration (VHA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a retrospective cohort study analyzing veterans with T2DM first prescribed an incretin therapy or a TZD between January 1, 2011, and December 31, 2021. A diagnosis of pancreatitis within 365 days of being prescribed either therapy was counted as a positive case. Data was collected and analyzed utilizing VA\u2019s Informatics and Computing Infrastructure (VINCI) and an adjusted odds ratio was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The TZD cohort consisted of 42\u2009912 patients compared with the incretin cohort of 304\u2009811 patients. The TZD cohort had a pancreatitis incidence rate of 1.94 cases per 1000 patients. The incretin cohort had a incidence rate of 2.06 cases per 1000 patients. An adjusted odds ratio found no statistical difference of pancreatitis cases between the TZD and incretin cohorts (adjusted odds ratio [AOR] = 0.94, 95% CI [0.75, 1.18]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>This retrospective cohort study of national VHA data found a relatively low incidence of pancreatitis in both cohorts, and an adjusted odds ratio found no statistical difference of pancreatitis in patients prescribed an incretin therapy compared with a control group. This data adds to growing evidence that incretin therapies do not seem to be associated with an increased risk of developing pancreatitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231205490","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T04:39:58Z","timestamp":1698295198000},"page":"685-689","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration"],"prefix":"10.1177","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-6509","authenticated-orcid":false,"given":"Kristen","family":"Wilhite","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Veterans Affairs Medical Center, Louisville, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Meyer","family":"Reid","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Veterans Affairs Health Care System, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lane","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Veterans Affairs Health Care System, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"bibr1-10600280231205490","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v5.i4.405"},{"key":"bibr2-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.09.043"},{"key":"bibr3-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.218"},{"key":"bibr4-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2016.07.004"},{"key":"bibr5-10600280231205490","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.1427"},{"key":"bibr6-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2010.02.002"},{"issue":"2","key":"bibr7-10600280231205490","first-page":"98","volume":"148","author":"Schachar E","year":"2009","journal-title":"Harefuah"},{"key":"bibr8-10600280231205490","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.12852.1"},{"key":"bibr9-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2019-137186"},{"key":"bibr10-10600280231205490","doi-asserted-by":"publisher","DOI":"10.3390\/ph14060586"},{"key":"bibr11-10600280231205490","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.02.24"},{"key":"bibr12-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2018.11.008"},{"key":"bibr13-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31773-2"},{"key":"bibr14-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4573"},{"key":"bibr15-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173037"},{"key":"bibr16-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.2720"},{"key":"bibr17-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.838550"},{"key":"bibr18-10600280231205490","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2015.1091944"},{"key":"bibr19-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2015.02.013"},{"key":"bibr20-10600280231205490","doi-asserted-by":"publisher","DOI":"10.15386\/cjmed-804"},{"key":"bibr21-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000008952"},{"key":"bibr22-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.1522"},{"key":"bibr23-10600280231205490","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2747"},{"key":"bibr24-10600280231205490","unstructured":"FDA AEs Reportying System (FAERS) public dashboard. FDA. Accessed January 1, 2023. https:\/\/www.fda.gov\/drugs\/guidancecomplianceregulatoryinformation\/surveillance\/adversedrugeffects\/ucm070093.htm"},{"key":"bibr25-10600280231205490","unstructured":"VA Adverse Drug Event Reporting System (VA ADERS). Department of Veterans Affairs. Accessed January 1, 2023. https:\/\/vaww.cmop.med.va.gov\/MedSafe_Portal\/."},{"key":"bibr26-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12297"},{"key":"bibr27-10600280231205490","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-2212"},{"key":"bibr28-10600280231205490","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. https:\/\/www.R-project.org\/"},{"key":"bibr29-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1270-y"},{"key":"bibr30-10600280231205490","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3231-y"},{"issue":"463","key":"bibr31-10600280231205490","first-page":"22","volume":"485","author":"Vespa JE.","year":"2020","journal-title":"World War II (December 1941 to December 1946)"},{"key":"bibr32-10600280231205490","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10020300"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231205490","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231205490","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231205490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:24Z","timestamp":1777374804000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231205490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1177\/10600280231205490"],"URL":"https:\/\/doi.org\/10.1177\/10600280231205490","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]}}}